ramipril + placebo

This entry refers to the combination of ramipril, an angiotensin-converting enzyme (ACE) inhibitor, and placebo as used in clinical trials. Ramipril is a small molecule antihypertensive agent that works by inhibiting ACE, thereby reducing the production of angiotensin II, leading to vasodilation and decreased blood pressure. It is primarily indicated for hypertension, heart failure, and reduction of cardiovascular events in high-risk patients. Placebo is an inert substance with no pharmacological effect and serves as a control in randomized controlled trials to assess the efficacy and safety of active drugs like ramipril[1][2][10]. The combination "ramipril + placebo" does not represent a marketed pharmaceutical product but rather denotes two separate arms or groups within clinical studies.